TABLE OF CONTENTS
1 INTRODUCTION 39
1.1 OBJECTIVES OF THE STUDY 39
1.2 MARKET DEFINITION 39
1.3 OVERVIEW OF THE NORTH AMERICA OPHTHALMOLOGY LASERS MARKET 39
1.4 CURRENCY AND PRICING 41
1.5 LIMITATIONS 41
1.6 MARKETS COVERED 41
2 NORTH AMERICA OPHTHALMOLOGY LASERS MARKET: SEGMENTATION 44
2.1 MARKETS COVERED 44
2.2 GEOGRAPHICAL SCOPE 45
2.3 YEARS CONSIDERED FOR THE STUDY 46
2.4 DBMR TRIPOD DATA VALIDATION MODEL 47
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 50
2.6 MULTIVARIATE MODELLING 51
2.7 PRODUCT LIFELINE CURVE 51
2.8 DBMR MARKET POSITION GRID 52
2.9 VENDOR SHARE ANALYSIS 54
2.10 MARKET END USER COVERAGE GRID 55
2.11 SECONDARY SOURCES 56
3 EXECUTIVE SUMMARY 57
4 PREMIUM INSIGHTS 59
4.1 PORTERS FIVE FORCES 60
4.2 PESTEL ANALYSIS 61
4.3 STRATEGIC INITIATIVES 62
5 NORTH AMERICA OPHTHALMOLOGY LASERS MARKET, REGULATION 63
6 MARKET OVERVIEW 65
6.1 DRIVERS 67
6.1.1 INCREASING INCIDENCES OF CHRONIC AND COMMUNICABLE EYE DISEASES 67
6.1.2 INCREASED CONSUMER AWARENESS FOR LASER TREATMENTS 67
6.1.3 INCREASING ADOPTION OF OUTPATIENT PROCEDURES 68
6.1.4 RISING DEMAND FOR MINIMALLY INVASIVE SURGICAL PROCEDURES 69
6.2 RESTRAINTS 70
6.2.1 HIGH COST OF OPHTHALMOLOGY LASER PROCEDURES 70
6.2.2 STRINGENT REGULATORY POLICIES 70
6.3 OPPORTUNITIES 71
6.3.1 TECHNOLOGICAL ADVANCEMENTS IN OPHTHALMOLOGY 71
6.3.2 EMERGING MARKETS AND GOVERNMENT FUNDING 72
6.4 CHALLENGES 73
6.4.1 LACK OF SKILLED PROFESSIONALS 73
6.4.2 SAFETY CONCERNS 73
7 NORTH AMERICA OPHTHALMOLOGY LASERS MARKET, BY PRODUCT 75
7.1 OVERVIEW 76
7.2 EXCIMER LASERS 79
7.2.1 ARF 80
7.2.2 KRF 80
7.2.3 XECL 80
7.2.4 XEFL 80
7.2.5 F2 80
7.2.6 XEBR 80
7.3 FEMTOSECOND LASERS 80
7.3.1 SEMICONDUCTOR LASERS 81
7.3.2 SOLID-STATE BULK LASERS 82
7.3.3 FREQUENCY-CONVERTED SOURCES 82
7.3.4 FIBER LASERS 82
7.3.5 DYE LASERS 82
7.3.6 OTHERS 82
7.4 ND:YAG LASERS 82
7.4.1 ND: YAG LASER AT 1064 NM 83
7.4.2 ND: YAG GREEN LASER AT 532 NM 83
7.5 DIODE LASERS 83
7.6 OTHERS 84
8 NORTH AMERICA OPHTHALMOLOGY LASERS MARKET, BY TYPE 85
8.1 OVERVIEW 86
8.2 PHOTOCOAGULATION LASERS 89
8.3 SELECTIVE LASER TRABECULOPLASTY (SLT) 89
8.4 PHOTODISRUPTION LASERS 90
9 NORTH AMERICA OPHTHALMOLOGY LASERS MARKET, BY APPLICATION 92
9.1 OVERVIEW 93
9.2 THERAPEUTICS 96
9.2.1 CATARACT REMOVAL 97
9.2.2 GLAUCOMA TREATMENT 97
9.2.3 DIABETIC RETINOPATHY TREATMENT 97
9.2.4 REFRACTIVE ERROR CORRECTION 97
9.2.5 AMD TREATMENT 97
9.2.6 OTHERS 97
9.3 DIAGNOSTICS 98
9.3.1 OPTICAL COHERENCE TOMOGRAPHY (OCT) 99
9.3.2 SCANNING LASER OPHTHALMOSCOPE (SLO) 99
10 NORTH AMERICA OPHTHALMOLOGY LASERS MARKET, BY GASES 100
10.1 OVERVIEW 101
10.2 NOBLE GAS 104
10.2.1 ARGON 105
10.2.2 XENON 105
10.2.3 KRYPTON 105
10.3 HALOGEN GAS 105
10.3.1 CHLORINE 106
10.3.2 BROMINE 106
10.3.3 FLOURINE 106
10.4 BUFFER GAS 106
10.4.1 HELIUM 107
10.4.2 NEON 107
10.5 OTHERS 108
11 NORTH AMERICA OPHTHALMOLOGY LASERS MARKET, BY END USER 109
11.1 OVERVIEW 110
11.2 HOSPITALS 113
11.3 CLINICS 113
11.4 OTHERS 114
12 NORTH AMERICA OPHTHALMOLOGY LASERS MARKET, BY REGION 116
12.1 NORTH AMERICA 117
12.1.1 U.S. 125
12.1.2 CANADA 129
12.1.3 MEXICO 133
13 NORTH AMERICA OPHTHALMOLOGY LASERS MARKET: COMPANY LANDSCAPE 137
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 137
14 SWOT ANALYSIS 138
15 NORTH AMERICA OPHTHALMOLOGY LASERS MARKET, CPS 139
15.1 BAUSCH & LOMB INCORPORATED 139
15.1.1 COMPANY SNAPSHOT 139
15.1.2 REVENUE ANALYSIS 139
15.1.3 COMPANY SHARE ANALYSIS 140
15.1.4 PRODUCT PORTFOLIO 140
15.1.5 RECENT DEVELOPMENT 140
15.2 JOHNSON & JOHNSON, INC. 141
15.2.1 COMPANY SNAPSHOT 141
15.2.2 REVENUE ANALYSIS 141
15.2.3 COMPANY SHARE ANALYSIS 142
15.2.4 PRODUCT PORTFOLIO 142
15.2.5 RECENT DEVELOPMENT 142
15.3 ZEISS 143
15.3.1 COMPANY SNAPSHOT 143
15.3.2 REVENUE ANALYSIS 143
15.3.3 COMPANY SHARE ANALYSIS 144
15.3.4 PRODUCT PORTFOLIO 144
15.3.5 RECENT DEVELOPMENT 144
15.4 ALCON 145
15.4.1 COMPANY SNAPSHOT 145
15.4.2 REVENUE ANALYSIS 145
15.4.3 COMPANY SHARE ANALYSIS 146
15.4.4 PRODUCT PORTFOLIO 146
15.4.5 RECENT DEVELOPMENT 146
15.5 NIDEK CO., LTD 147
15.5.1 COMPANY SNAPSHOT 147
15.5.2 REVENUE ANALYSIS 147
15.5.3 COMPANY SHARE ANALYSIS 148
15.5.4 PRODUCT PORTFOLIO 148
15.5.5 RECENT DEVELOPMENT 148
15.6 ARC LASER GMBH 149
15.6.1 COMPANY SNAPSHOT 149
15.6.2 PRODUCT PORTFOLIO 149
15.6.3 RECENT DEVELOPMENT 149
15.7 AUROLAB 150
15.7.1 COMPANY SNAPSHOT 150
15.7.2 PRODUCT PORTFOLIO 150
15.7.3 RECENT DEVELOPMENT 150
15.8 CALMAR LASER 151
15.8.1 COMPANY SNAPSHOT 151
15.8.2 PRODUCT PORTFOLIO 151
15.8.3 RECENT DEVELOPMENT 151
15.9 IRIDEX CORPORATION 152
15.9.1 COMPANY SNAPSHOT 152
15.9.2 REVENUE ANALYSIS 152
15.9.3 PRODUCT PORTFOLIO 153
15.9.4 RECENT DEVELOPMENT 153
15.10 IVIS TECHNOLOGIES 154
15.10.1 COMPANY SNAPSHOT 154
15.10.2 PRODUCT PORTFOLIO 154
15.10.3 RECENT DEVELOPMENT 154
15.11 LENSAR, INC. 155
15.11.1 COMPANY SNAPSHOT 155
15.11.2 REVENUE ANALYSIS 155
15.11.3 PRODUCT PORTFOLIO 156
15.11.4 RECENT DEVELOPMENT 156
15.12 LUMENIS BE LTD. 157
15.12.1 COMPANY SNAPSHOT 157
15.12.2 PRODUCT PORTFOLIO 157
15.12.3 RECENT DEVELOPMENT 157
15.13 LIGHTMED 158
15.13.1 COMPANY SNAPSHOT 158
15.13.2 PRODUCT PORTFOLIO 158
15.13.3 RECENT DEVELOPMENT 158
15.14 MEDA CO., LTD. 159
15.14.1 COMPANY SNAPSHOT 159
15.14.2 PRODUCT PORTFOLIO 159
15.14.3 RECENT DEVELOPMENT 159
15.15 OD-OS 160
15.15.1 COMPANY SNAPSHOT 160
15.15.2 PRODUCT PORTFOLIO 160
15.15.3 RECENT DEVELOPMENT 160
15.16 QUANTEL MEDICAL (A SUBSIDIARY OF LUMIBIRD MEDICAL) 161
15.16.1 COMPANY SNAPSHOT 161
15.16.2 REVENUE ANALYSIS 161
15.16.3 PRODUCT PORTFOLIO 162
15.16.4 RECENT DEVELOPMENT 162
15.17 SCHWIND EYE-TECH-SOLUTIONS 163
15.17.1 COMPANY SNAPSHOT 163
15.17.2 PRODUCT PORTFOLIO 163
15.17.3 RECENT DEVELOPMENT 163
15.18 TOPCON 164
15.18.1 COMPANY SNAPSHOT 164
15.18.2 REVENUE ANALYSIS 164
15.18.3 PRODUCT PORTFOLIO 165
15.18.4 RECENT DEVELOPMENT 165
15.19 ZIEMER OPHTHALMIC SYSTEMS AG 166
15.19.1 COMPANY SNAPSHOT 166
15.19.2 PRODUCT PORTFOLIO 166
15.19.3 RECENT DEVELOPMENT 166
16 QUESTIONNAIRE 167
17 RELATED REPORTS 170

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.